Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.12976 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Emi Nakatsugawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan. Hauptthemen laut MEDLINE: Cachexia, Analgesics, Opioid, Naltrexone, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background/Objectives Clinical responses to naldemedine vary between individuals with advanced cancer. This is a prospective, single‐center, observational study aimed to evaluate the influence of genetic polymorphisms and cachexia status on plasma naldemedine and clinical responses.
Methods
Forty‐eight patients being treated with naldemedine for opioid‐induced constipation under treatment of cancer pain were enrolled. Plasma naldemedine concentrations were determined on the fourth day or later after administration of naldemedine, and the associations with genotypes, cachexia status, and clinical responses were assessed.
Results
Cancer patients exhibited a large variation in the plasma naldemedine concentrations, and it was correlated with serum total protein level. Patients who were homozygous CYP3A5*3 had a higher plasma concentration of naldemedine than those with the *1 allele. ABCB1 genotypes tested in this study were not associated with plasma naldemedine. A negative correlation was observed between the plasma naldemedine concentration and 4β‐hydroxycholesterol level. The plasma naldemedine concentration was lower in patients with refractory cachexia than in those with precachexia and cachexia. While serum levels of interleukin‐6 (IL‐6) and acute‐phase proteins were higher in patients with refractory cachexia, they were not associated with plasma naldemedine. A higher plasma concentration of naldemedine, CYP3A5*3/*3 , and an earlier naldemedine administration after starting opioid analgesics were related to improvement of bowel movements.
Conclusion
Plasma naldemedine increased under deficient activity of CYP3A5 in cancer patients. Cachectic patients with a higher serum IL‐6 had a lower plasma naldemedine. Plasma naldemedine, related to CYP3A5 genotype, and the initiation timing of naldemedine were associated with improved bowel movements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.
- Division of Palliative Care Center, Hamamatsu University Hospital, Hamamatsu, Japan.
ORCID-Profile: Takafumi Naito
Förderung
- JSPS KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Nakatsugawa, E., Naito, T., Shibata, K., Kitajima, R., & Kawakami, J. (2024). Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12976
Vancouver
Nakatsugawa E, Naito T, Shibata K, Kitajima R, Kawakami J. Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12976
BibTeX
@article{Nakatsugawa2024,
author = {Nakatsugawa, Emi and Naito, Takafumi and Shibata, Kaito and Kitajima, Ryo and Kawakami, Junichi},
title = {Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.12976}
}
EUVIMED